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Dosimetric verifi cation of dose optimisation 
algorithm during endovascular brachythera-
py of the peripheral vessels
Grzegorz ZWIERZCHOWSKI, Julian MALICKI, Janusz SKOWRONEK
ABSTRACT
AIM: Dosimetric verifi cation of the dose optimisation model used in endovascular brachytherapy, 
evaluation of the optimised dose distributions using elaborated indices.
BACKGROUND: The equipment used for standard radiotherapy is used in vascular brachytherapy for 
prevention of restenosis after angioplasty.
MATERIAL AND METHOD: A paraffi n-wax phantom, thermoluminescent detectors and MD-55 
Gafchromic® fi lms were used for dose measurements. The edge dose index (EDI), central dose index 
(CDI) and treatment length index (TLI) were introduced to compare dose distributions calculated and 
measured.
RESULTS: Obtained values (p>0.05) show no statistically signifi cant differences between calculated 
doses and measured doses. EDI values showed improvement in dose homogeneity on the edges of 
the application after optimisation. After optimisation CDI values from 0.9% to 1.6% for calculated and 
from -1.8% to 3.1% for measured showed improvement in dose homogeneity in the central part of 
the application. Observed values of TLI from 3% to 21% for calculated doses and from 7% to 24% for 
doses measured by Gafchromic® fi lms showed increase of RIL for optimised treatment plans.
CONCLUSIONS: 1/ The designed phantom allowed repeatable dosimetric verifi cation of dose distri-
butions in endovascular brachytherapy. 2/ Measurements with thermoluminescent detectors and 
Gafchromic fi lms proved the accuracy of the calculation algorithm in endovascular brachytherapy 
conditions. 3/ Elaborated indices were found to be a useful tool in describing dose homogeneity. They 
allowed the process of optimisation to be controlled and thus an increase in dose homogeneity by 
30% at the edges and by 7% in the middle of the treated volume to be achieved.
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BACKGROUND
Treatment methods of atherosclerotic disease 
of peripheral vessels were limited to vascular 
bypass surgery until 1977, when Gruentzig 
introduced percutaneous transluminal an-
gioplasty (PTA) to medical practice [1, 2, 3]. 
However, a signifi cant fraction of patients 
after PTA developed symptoms of recurrent 
vessel narrowing due to the process of rest-
enosis. During PTA treatment the stenotic 
part of the artery undergoes high pressure of 
14 to 18 atmospheres, which involves several 
biological processes inside smooth muscle 
cells which lead to accelerated proliferation 
of cells in the treated part of the vessel. The 
paradigm elaborated for standard radiother-
apy was introduced as the start of vascular 
brachytherapy for the prevention of restenosis 
after angioplasty procedures [4]. Intravascu-
lar brachytherapy prevents inward remodel-
ling and induces an increase in lumen area 
but partially prevents healing of the disrupted 
vessel surface [5, 6, 7, 8]. Standard brachyther-
apy equipment is used (microSelectron HDR 
with 370 GBq Ir -192 source). Intervention 
length (IL) defi ned by the angioplasty length 
of PTA should be covered with a homogeneous 
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dose of 12 to 20 Gy with additional margin of 
10 mm for the most distal and proximal part 
of the injured vessel wall.
Multiple clinical trials have shown that en-
dovascular brachytherapy has reduced the 
risk of restenosis from 30–60% to 5–15%, if 
the irradiation is planned to meet individual 
needs and is delivered accurately. However, 
using irradiation for treatment inside the ves-
sel requires dose verifi cation, which is much 
more diffi cult than in other brachytherapy 
techniques because in vivo dose checks are 
almost impossible [9, 10, 11, 12, 13, 14].
AIM OF THE STUDY
The aim of the study was dosimetric verifi ca-
tion of the dose optimisation model used in en-
dovascular brachytherapy and evaluation of 
the optimised dose distributions using elabo-
rated indices.
MATERIAL AND METHOD
The set-up of irradiated volume required defi -
nition of certain parameters presented below 
in Figures 1 and 2. The reference isodose 
length (RIL) was defi ned as vessel length at 
the reference depth (RD) covered by 90% iso-
dose. The properties of dose distribution in 
such a set-up require that intervention length 
(IL) be shorter than RIL by about 10 mm. RIL 
describes dose distribution and depends on 
the isotope properties, reference depth (RD) 
and the source confi guration described by ac-
tive source length (ASL) [14, 15].
Intervention length (IL) is defi ned by the 
length of the vessel wall between the most 
distal and proximal parts of all infl ated bal-
loons used during the PTA procedure. Refer-
ence lumen diameter (RLD) is the lumen di-
ameter measured from media to media after 
angioplasty procedure. Active source length 
(ASL) is defi ned as the distance between the 
centre of the fi rst and the last stepping source 
position. Reference depth (RD) is defi ned as 
RLD/2 plus additional margin (r) of usually 2 
mm into the vessel wall [16, 17, 18, 19, 20].
Phantom description
The authors designed and constructed the 
paraffi n-wax phantom shown in Figure 3 and 
used it for the dose measurements. For 0.15 
to 0.85 weight fractions of the phantom com-
ponents the physical density of the phantom 
material is 0.93 g/cm3 (according to NIST).
The exchangeable layers made it possible to 
place thermoluminescent detectors or fi lms in 
a stable and reproducible way at chosen dis-
tances of RD= 5, 7 and 10 mm (from catheter 
axis to detector).
Dose measurements and statistical 
evaluation of the results 
Thermoluminescent detectors LiF 100 with 
TLD 3500 reader and MD-55 Gafchromic® 
dosimetry media were used as dosimeters 
[21]. Calibration of the LiF detectors and MD-
55 fi lms were performed using a Co-60 beam 
in reference conditions. Films were digitised 
using Microtek® ScanMaker 900i. The treat-
ment plans for 15 cases were prepared for ac-
tive source length ASL=25, 50, 75, 100 and 125 
mm, respectively. The dose at dose points was 
assumed for 10 Gy at the distances RD=5, 7 
and 10 mm from the axis of the catheter. Each 
set of calculations and measurements was 
carried out for the non-optimised and then for 
the optimised treatment plan. TLD detectors 
were placed inside the phantom in the places 
corresponding to positions of defi ned refer-
ence points. Gafchromic® fi lms were placed 
between the layers of the designed phantom at 
Fig. 1. Dose planning parameters in endovascular brachytherapy. 
IL (interventional length); ASL (active source length); RIL (refer-
ence isodose length)
 
 
 
Fig. 2. Defi nition of RIL based on dose distribution along the axis 
of the source arrangement [6, 12]
04_01.indd   115 2009-11-13   11:30
116 REP PRACT ONCOL RADIOTHER • 2009 • 14/4/: 114–121
ORIGINAL ARTICELS 
distances from the axis of the catheter equal 
to the chosen reference depths (RD). Mea-
surements were performed three times and 
mean values of the doses at the dose points 
were compared.
For the statistical evaluation of the obtained 
results (calculated doses vs. measured doses)
Wilcoxon matched pair test for dependent 
samples at a=0.05 was used. Next the calcu-
lated and measured doses were divided into 
two groups for every treatment plan. The 
fi rst group contained doses calculated and 
measured in the central part of the applica-
tion, and the second group contained doses 
calculated and measured at the edges of the 
application. Comparisons (edge vs. central 
part) were performed for unoptimised and op-
timised treatment plans respectively. Mann-
Whitney U test for independent samples was 
used at a=0.05.
Verification of the optimisation 
algorithm
For the treatment plan without optimisation, 
dwell times were equal for all source posi-
tions. Doses on the edge part of the treatment 
volume were lower than the prescribed ref-
erence dose, while in the central part of the 
application doses were higher than those pre-
scribed. After optimisation of the treatment, 
dwell times were different for particular ac-
tive source positions. Three indices, the edge 
dose index (EDI), central dose index (CDI) 
and treatment length index (TLI), were de-
fi ned and introduced to describe and compare 
dose distributions calculated and measured 
and the impact of the optimisation on doses. 
EDI is the difference between doses before 
and after the optimisation as a percentage of 
the dose after optimisation at the reference 
point at the edge of the applicator. So it de-
scribes the dose increase near the edge due 
to the applied optimisation procedure. The 
central dose index, CDI (CDIc – calculated, 
CDIm-measured), respectively describes the 
difference between the dose prescribed and 
calculated or measured at the reference point 
located in the middle of the active length. 
TLI describes the percentage increase of the 
length of the RIL (reference isodose length) 
after the optimisation procedure.
Clinically, the fi rst two indices, EDI and 
CDI, show the changes in dose homogene-
ity around the applicator, while TLI detects 
changes in treatment volume.
All indices were determined for calculated 
and measured doses, and marked by lower 
case c or m, respectively, as presented in equa-
tions 1–3.
EDIc =
 Dc(o) – Dc(uo)  100%
                    Dc(o) 
EDIc =
 Dm(o) – Dm(uo)  100%
                   Dm(o) 
where: c(uo), Dm(uo) D are calculated and mea-
sured doses for non-optimised treatment plan, 
Dc(o), Dm(o) calculated and measured doses for 
optimised treatment plan, respectively.
CDIm =
 CDm – DREF  100%
                  CDm
CDIc =
 CDc – DREF  100%
                 CDc
where: CDc – dose in the central part of the 
application calculated, Cm – dose in the cen-
tral part of the application measured by TLD, 
DREF – reference dose (10 Gy).
TLIc =
 RILc(o) – RILc(uo)  100%
                    RILc(o) 
TLIm =
 RILm(o) – RILm(uo)  100%
                   RILm(o) 
where: RILc(uo) – calculated RIL for unopti-
mised treatment plan, RILc(o) – calculated RIL 
Fig. 3. The paraffi n wax phantom with three exchangeable layers 
providing set-up of reference depths of 5, 7 and 10 mm from the 
axis of a standard 6F catheter
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for optimised treatment plan, RILm(uo) – mea-
sured RIL for unoptimised treatment plan, 
RILm(o) – measured RIL for optimised treat-
ment plan.
RESULTS
The designed phantom allowed conditions 
of endovascular brachytherapy to be recon-
structed and dose distributions calculated by 
the treatment planning system to be verifi ed. 
The plot of calculated and measured doses at 
the conditions chosen as an example (depth of 
5 mm, ASL of 100 mm) is presented in Figure 
4. The left part of the fi gure represents doses 
for the non-optimised treatment plan and the 
right part for the optimised plan.
The results of the statistical analysis of the 
doses in dose points calculated by Plato 14.3 
versus those measured with TLD dosimeters 
and Gafchromic® fi lms are shown in Table 1.
The comparisons were done for unoptimised 
and optimised treatment plans for ASL= 25, 
50, 75, 100 and 125 mm and RD = 5, 7, and 10 
mm, respectively. Wilcoxon test was used.
Obtained values (p>0.05) for most treat-
ment plans show no statistically signifi cant 
differences between calculated doses and dos-
es measured by TLD dosimeters and Gafchro-
mic® fi lms. The same results were obtained for 
unoptimised and optimised treatment plans.
Results of the comparison between doses 
from the edges and central part of the applica-
tion for ASL= 25, 50, 75, 100 and 125 mm and 
RD = 5, 7, and 10 mm are shown in Table 2. 
Doses calculated and measured with TLD and 
Gafchromic® fi lms were taken into account for 
optimised and unoptimised treatment plans, 
respectively. Mann-Whitney U test at a=0.05 
was used.
Obtained p values show that only for unop-
timised treatment plans did statistically sig-
nifi cant differences occur – between the doses 
(in dose points), lying in the middle and at the 
edges of the active length. This result shows 
inhomogeneity in dose distributions before 
the optimisation procedure was applied. Simi-
lar results were obtained for doses calculated 
and those measured with thermoluminescent 
detectors and Gafchromic® fi lms. After the 
optimisation procedure p values showed no 
statistically signifi cant differences between 
doses (at dose points) lying at the edges and in 
the middle of the active length, for both calcu-
lations and measurements.
In Table 3 the edge dose index (EDI) is 
shown for doses calculated (Plato) and mea-
sured, for ASL= 25, 50, 75 100 and 125 mm.
For ASL = 25, 50, 75, 100 and 125 mm and 
chosen reference depths of 5, 7 and 10 mm cor-
responding values of CDI are listed in Table 4 
and the percentage difference between doses 
calculated/measured and reference dose (10 
Gy) prescribed in the central part of the appli-
cation is shown. Values obtained for treatment 
plans with optimisation are presented with a 
grey background.
CDI values for the unoptimised treatment 
plan show that in the central part of the treat-
ment length, doses were higher by 3% to 10% 
than prescribed, for calculated and measured 
values. After optimisation CDI values from 
0.9% to 1.6% for calculated and from -1.8% to 
 
Fig. 4. Calculated and measured doses for ASL = 100 mm and 
RD = 5mm. Gray line with squares – doses calculated by Plato; 
black line with triangles – doses measured by TLD dosimeters; 
Black line with squares – doses measured by Gafchromic fi lms
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(Wilcoxon)p
Unoptimised Optimised
ASL [mm] RD [mm] Plato vs. TLD Plato vs. GAF Plato vs. TLD Plato vs. GAF
25
5 0.917 0.600 0.059 0.249
7 0.600 0.249 0.345 0.116
10 0.093 0.249 0.917 0.138
50
5 0.374 0.182 0.450 0.398
7 0.859 0.230 0.689 0.213
10 0.965 0.859 0.155 0.010
75
5 0.100 0.289 0.569 0.453
7 0.379 0.164 1.000 0.423
10 0.148 0.103 0.103 0.569
100
5 0.192 0.476 0.754 0.237
7 0.281 0.781 0.076 0.099
10 0.313 0.385 0.566 0.313
125
5 0.424 0.162 0.110 0.148
7 0.182 0.121 0.073 0.431
10 0.732 0.233 0.431 0.118
Table 1. Calculated vs. measured dose distributions for unoptimised and optimised treatment plans, Wilcoxon Test at a=0.05
(U Mann-Whitney) p
Unoptimised Optimised
ASL [mm] RD [mm] Plato TLD GAF Plato TLD GAF
25
5 0.064 0.064 0.064 1.000 1.000 0.240
7 0.057 0.064 0.355 1.000 0.165 0.348
10 0.057 0.064 0.064 1.000 1.000 0.165
50
5 0.006 0.006 0.028 0.352 0.100 0.463
7 0.006 0.018 0.006 0.853 0.715 0.410
10 0.006 0.028 0.011 0.357 0.584 0.715
75
5 0.001 0.002 0.024 0.395 0.462 0.345
7 0.001 0.001 0.001 0.089 0.092 0.247
10 0.002 0.002 0.005 0.671 0.430 0.318
100
5 0.002 0.041 0.025 1.000 0.222 0.522
7 0.002 0.047 0.003 1.000 0.035 0.370
10 0.002 0.054 0.004 0.561 0.848 0.142
125
5 0.001 0.074 0.052 0.651 0.156 0.141
7 0.001 0.010 0.046 0.643 0.208 0.246
10 0.001 0.002 0.001 1.000 0.344 0.916
Table 2. Doses from the edges vs. doses from central part of the application for treatment plans before and after optimisa-
tion U Mann-Whitney Test at a=0.05
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RD=5 mm RD=7 mm RD=10 mm
ASL [mm] EDIC EDImTLD EDImGAF EDIC EDImTLD EDImGAF EDIC EDImTLD EDImGAF
25 15.6 11.4 19.6 14.2 15.1 18.3 10.0 10.8 18.5
50 21.9 23.5 28.3 22.1 23.2 33.3 19.6 22.3 28.1
75 24.7 25.2 34.6 25.5 27.5 38.0 24.0 29.0 34.2
100 26.3 28.9 16.0 27.6 28.0 40.3 26.6 25.3 18.2
125 27.3 29.0 35.8 28.8 30.2 39.7 28.3 29.2 39.0
Table 3. The edge dose index for calculated and measured doses at chosen reference depths (RD) of 5, 7 and 10 mm 
for ASL = 25, 50 ,75, 100 and 125 mm
RD=5 mm RD=7 mm RD=10 mm
ASL [mm] CDIC CDImTLD CDImGAF CDIC CDImTLD CDImGAF CDIC CDImTLD CDImGAF
25 10.1 8.3 8.8 11.1 7.8 3.4 11.1 9.0 10.2
-0.4 -0.9 1.6 -0.4 -0.9 1.6 -1.0 -1.8 1.2
50 7.7 8.9 5.3 9.1 8.4 8.2 10.2 7.7 11.9
0.0 0.3 0.4 -0.1 0.3 0.6 -0.3 0.8 3.1
75 6.2 6.3 5.6 7.6 7.4 8.4 9.0 8.2 8.7
0.0 0.6 1.3 0.1 1.4 1.6 -0.1 -0.1 1.2
100 5.6 3.6 6.1 7.1 6.6 7.3 8.7 7.6 7.5
0.0 1.2 -0.9 0.0 0.7 0.1 0.1 -0.4 0.0
125 5.0 5.4 4.5 6.3 7.1 5.2 7.9 8.2 8.3
0.0 -0.6 0.6 0.0 1.7 1.7 0.0 1.0 2.0
Table 4. Central dose index values for unoptimised and optimised (grey background) treatment plans for ASL= 25, 50, 75, 
100 and 125 mm
TLIC[%]
RD [mm] ASL=25 mm ASL=50 mm ASL=75 mm ASL=100 mm ASL=125 mm
5 18.5 9.1 8.9 7.6 3.1
7 20.7 13.2 13.8 9.3 6.0
10 18.5 16.7 12.3 8.9 5.5
TLImGAF[%]
RD[mm] ASL=25 mm ASL=50 mm ASL=75 mm ASL=100 mm ASL=125 mm
5 21.5 11.8 11.2 9.6 6.5
7 22.0 14.8 15.9 11.5 8.7
10 24.0 20.7 10.3 13.0 6.3
Table 6. Treatment length index values – percentage increase of RIL after optimisation of the treatment plans for ASL= 25, 
50, 75, 100 and 125 mm
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3.1% for measured doses were observed. CDI 
values showed improvement in dose homoge-
neity in the central part of the application af-
ter optimisation.
In Table 5 values of the treatment length in-
dex (TLI) are shown as a percentage increase 
of reference isodose length after optimisa-
tion of the treatment plans, for ASL= 25, 50, 
75, 100, 125 mm and chosen RD values of 5, 
7 and 10 mm. TLI values shown in this table 
are based on calculations from the treatment 
planning system (TLIC) and dose values ob-
tained from measurements with Gafchromic® 
fi lms (TLImGAF).
Observed values of TLI from 3% to 21% for 
calculated doses and from 7% to 24% for doses 
measured by Gafchromic® fi lms showed in-
crease of RIL for optimised treatment plans. 
After optimisation of the dwell times vessel 
lengths covered by the reference isodose were 
higher by 5 mm to 14 mm without increase of 
ASL.
DISCUSSION
Calculated and measured doses at dose points 
were compared using the Wilcoxon matched 
pair test for dependent samples at alpha value 
= 0.05. For dose values calculated and mea-
sured, and ASL= 25, 50, 75, 100 and 125 mm, 
obtained p values for treatment plans without 
optimisation and for optimised plans show no 
statistically signifi cant differences between 
calculated doses and doses measured by TLD 
dosimeters and those obtained from Gafchro-
mic® fi lms (Table 1).
Calculated and measured doses for every 
ASL were divided into three groups containing 
an equal number of points – two groups from 
the edges of the application and one group 
from the central part. Points from the edges 
were used to form one group containing points 
for both ends, and compared with doses from 
points from the central part of the application. 
Doses from the edges were compared to doses 
from the central part of the application using 
Mann-Whitney U test for independent samples 
at alpha value = 0.05. Obtained p values pre-
sented in Table 2 show that only for unopti-
mised treatment plans were there statistically 
signifi cant differences between doses at the 
centre and at the edges of the applications 
for calculated doses and for measured doses 
(TLD and Gafchromic® fi lms).
Edge dose index was previously defi ned as 
percentage increase of the doses at the edges of 
the application after optimisation of the treat-
ment plan. Values of EDI (Table 3) showed 
in general 10 to 40% increase of the dose at 
the edges of the application for the optimised 
treatment plan for doses calculated and mea-
sured with TLD and Gafchromic fi lms. For 
the unoptimised treatment plan doses at the 
dose points located at the central part of the 
application are in general higher by 5 to 12% 
for calculated and measured doses than the 
prescribed doses to the reference dose points. 
This is shown by higher values of CDI for the 
unoptimised treatment plan (Table 4). After 
optimisation of the treatment plan lower cen-
tral dose index values (Table 5) showed that 
the doses differ by not more than 1 to 2.8% 
from the prescribed reference dose (10 Gy) at 
the centre of the application for both calculat-
ed and measured values.
Treatment length index values presented in 
Table 5 show the percentage increase of the 
length of RIL after optimisation of the treat-
ment plan. RIL length values based on calcu-
lations and measurements are higher in gen-
eral by 9 to 24% when the treatment plan is 
optimised. Increase of RIL after treatment 
plan optimisation showed that increasing ASL 
is not necessary for particular PTL. After op-
timisation of the treatment plan, it is possible 
to avoid underdosage at the edges of the treat-
ment length. For the central part of the ap-
plication, the dose is closer to the prescribed 
reference value. Dose distribution is more 
homogeneous and this is advantageous from 
a clinical point of view. The probability of a 
“geographical miss” is lower for the optimised 
treatment plan.
CONCLUSIONS
1. The designed and constructed phantom 
allowed for reliable and repeatable dosimetric 
verifi cation of dose distributions in endovas-
cular brachytherapy.
2. Measurements with thermoluminescent 
detectors and Gafchromic® fi lms proved the 
accuracy of the calculation algorithm in endo-
vascular brachytherapy conditions.
3. Elaborated indices were found to be a use-
ful tool in describing dose homogeneity around 
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the applicator in endovascular brachytherapy. 
They allowed the process of optimisation to be 
controlled and thus an increase in dose homo-
geneity by 30% at the edges and by 7% in the 
middle of the treated volume to be achieved.
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